New drug price determination process needs fundamental reform.

In a meeting on the subject of "Problems and reform programs for the drug pricing system of Korea" on May 11 sponsored by several civic groups, Mr. Woo Seok-gyun of the Korean Federation of Medical Groups for Health Rights (KFHR) said that the new drug price determination should be fundamentally reformed after pointing out that about 100 patent expired drugs still enjoyed their patent protectio...